Krishan Nagpal, MD
Ophthalmology · Elmhurst, ILNPI 1326123381
Payments from drug & device makers
Across 120 payments — averaging $65.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Bausch & Lomb Americas Inc.$678
- Aerie Pharmaceuticals, Inc.$648
- Alcon$528
- Oyster Point Pharma, Inc.$477
- Regeneron Healthcare Solutions, Inc.$351
- plus $2K from 13 others
What the payments were for
- Consulting fees$2,07527%
- Food & beverage$5,66873%
- Education$180%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $3,321 |
| Bausch & Lomb Americas Inc. | 12 | $678 |
| Aerie Pharmaceuticals, Inc. | 8 | $648 |
| Alcon | 7 | $528 |
| Oyster Point Pharma, Inc. | 14 | $477 |
| Regeneron Healthcare Solutions, Inc. | 3 | $351 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $332 |
| Novartis | 8 | $270 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $225 |
| Sun Pharmaceutical Industries Inc. | 3 | $177 |
| Mallinckrodt Hospital Products Inc. | 6 | $165 |
| Shire North American Group Inc | 1 | $122 |
| Sight Sciences, Inc. | 1 | $121 |
| Dompe US, Inc. | 1 | $120 |
| Glaukos Corporation | 1 | $117 |
| NEW World Medical,inc. | 2 | $74 |
| Carl Zeiss Meditec, Inc. | 1 | $32 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Eyepoint US, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$1,600
- Rhopressa$581
- Rocklatan$581
- OZURDEX$475
- XIIDRA$459
- EYLEA$351
- MIEBO$350
- AcrySof$148
- CEQUA$130
- Hydrus Microstent$129
- VYZULTA$124
- LUMIGAN$123
- OMNI$121
- Oxervate$120
- Tecnis IOL$118
- iStent Trabecular Micro-Bypass Stent System$117
- iStent inject Trabecular Micro-Bypass Stent System$117
- Tecnis Simplicity$107
- TYRVAYA$105
- XEN GLAUCOMA TREATMENT SYSTEM$105
How this compares
$7,806 in reported general payments places this provider in the 80th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 46 | $66,734 |
| LumiganBimatoprost | 23 | $17,405 |
| Cyclosporine | 36 | $16,745 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $12,840 |
| VyzultaLatanoprostene Bunod | 18 | $7,317 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $4,764 |
| Latanoprost | 242 | $4,114 |
| Prednisolone Acetate | 62 | $2,492 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $1,915 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 102 | $1,481 |
| Dorzolamide Hcl | 52 | $1,481 |
| Brimonidine Tartrate | 22 | $1,476 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 20 | $1,234 |
| Ketorolac Tromethamine | 57 | $973 |
| Pilocarpine Hcl | 15 | $958 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $3,321 | $88,90380 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $648 | $12,84016 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $678 | $7,31718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Elmhurst
- Mateen AliniazeeElmhurst$122K
- Kevin KovachElmhurst$84K
- Saad AhmadElmhurst$64K
- Donald SandersElmhurst$62K
- Veeral ShethOak Forest$14.8M
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.9M
- Manjot GillChicago$1.4M
- Mitchell JacksonLake Villa$1.4M
- Ramanath BhandariSpringfield$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.